L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

Clinical trial NCT05878028 · UNKNOWN

Trial details

NCT number: NCT05878028
Sponsor: Quanli Gao
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2022-09-16
Primary completion: 2025-09-15
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.